Huayuan Securities released a research report on April 24 stating that it gave Jiudian Pharmaceutical (300705.SZ) a purchase rating. The main reasons for the rating include: 1) China has more than 300 million chronic pain patients, and gel patches have significant advantages as one of the preferred treatment methods; 2) loxoprofen sodium gel patches benefit from channel expansion+increased penetration rate of topical patches, and there is still plenty of room for growth; 3) Building a matrix of topical anti-inflammatory and analgesic products, and the follow-up pipeline is worth looking forward to. (Mainichi Keizai Shimbun)